Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno-Guard

Nitric Oxide - Biology and Chemistry

Volumn 9, Issue 2, 2003, Pages 103-110

  Panossian, A ^a   Hambartsumyan, M ^a   Panosyan, L ^a   Abrahamyan, H ^a   Mamikonyan, G ^a   Gabrielyan, E ^a   Amaryan, G ^b   Astvatsatryan, V ^b   Wikman, G ^c  

^a Pharmaceut/Nutraceuticals E   (Armenia)

^b YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^c Swedish Herbal Institute   (Sweden)

Author keywords

Andrographis paniculata; Capillary electrophoresis; Familial Mediterranean fever; Immuno Guard; Nitric oxide; Placebo controlled clinical trials

Indexed keywords

ANDROGRAPHOLIDE; COLCHICINE; ELEUTHEROSIDE E; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; IMMUNO GUARD CLINICAL A; INTERLEUKIN 6; NITRATE; NITRIC OXIDE; NITRITE; PLACEBO; SCHISANDRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CAPILLARY ELECTROPHORESIS; CHILD; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; IMMUNOMODULATION; INFLAMMATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANDROGRAPHIS; ANDROGRAPHIS PANICULATA;

EID: 0242493635     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2003.08.005     Document Type: Article

References (58)

1. Sohar E., Gafni J., Pras M., Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am. J. Med. 43:1967;227-253.
2. Centola M., Wood G., Frucht D.M., Galon J., Aringer M., Farrell C., Kingma D.W., Horwitz M.E., Mansfield E., Holland S.M., O'Shea J.J., Rosenberg H.F., Malech H.L., Kastner D.L. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood. 95:2000;3223-3231.
3. Schattner A., Gurevitz A., Zemer D., Hahn T. Induced TNF production in vitro as a test for familial Mediterranean fever. QJM. 89:1996;205-210.
4. Dilsen N., Gul A., Mege J.L., Sanguedolce M.V. Tumour necrosis factor in pathogenesis of familial Mediterranean fever. Am. J. Med. 93:1992;587.
5. Schattner A., Lachmi M., Livneh A., Pras M., Hahn T. Tumour necrosis factor in familial Mediterranean fever. Am. J. Med. 90:1991;434-438.
6. Direskeneli H., Ozdogan H., Korkmaz C., Akoglu T., Yazici H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J. Rheumatol. 26:1999;1983-1986.
7. Gang N., Drenth J.P., Langevitz P., Zemer D., Brezniak N., Pras M., van der Meer J.W., Livneh A. Activation of the cytokine network in familial Mediterranean fever. J. Rheumatol. 26:1999;890-897.
8. E. Erken, H.T.E. Ozer, R. Gunesacar, Plasma interleukin-10 levels in familial Mediterranean fever [abstract], in: Proceedings of the International Conference on Familial Mediterranean Fever II, Antalua, Turkey, vol. 73, 2000, p. B-8 (O).
9. S. Koz, M. Soyturk, S. Akar, B. Sengul, T.U. Yavuzsen, G. Kirkali, H. Resmi, M. Tunca, The interleukin 1 beta (IL-1) levels in attack and attack-free FMF patients and their first degree relatives [abstract], in: Proceedings of the International Conference on Familial Mediterranean Fever II, Antalua, Turkey, vol. 73, 2000, p. B-6 (P).
10. Notarnicola C., Didelot M.N., Seguret F., Demaille J., Touitou I. Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean fever. Genes Immun. 3:2002;43-45.
11. S. Oktem, T.U. Yavuzsen, B. Sengul, H. Akhunlar, H. Resmi, G. Kurkali, S. Akar, M. Tunca, Levels of interleukin-6 (IL-6) and its soluble receptor (sil-6R) in FMF patients during acute attack and attack-free period. [abstract], in: Proceedings of the International Conference on Familial Mediterranean Fever II, Antalua, Turkey, vol. 73, 2000, p. B-7(P).
12. Matzner Y., Abedat S., Shapiro E., Eisenberg S., Bar-Gil-Shitrit A., Stepensky P., Calco S., Azar Y., Urieli-Shoval S. Expression of the familial Mediterranean fever gene and activity of the C5a inhibitor in human primary fibroblast cultures. Blood. 96:2000;727-731.
13. Abedat S., Urieli-Shoval S., Shapira E., Calko S., Ben-Chetrit E., Matzner Y. Effect of colchicine and cytokines on MEFV expression and C5a inhibitor activity in human primary fibroblast cultures. Isr. Med. Assoc. J. 4:2002;7-12.
14. Muradkhanian K.S., Arakelov G.M. Changes in the concentration of histamine in the blood of patients and their relatives in familial cases of periodic disease. Zh. Eksp. Klin. Med. 11:1971;51-57.
15. Panossian A.G., Grigoryan S.V., Davtian D.G., Gevorkian G.A., Gabrielian E.S. Arachidonic acid metabolism in the platelets of patients with familial Mediterranean fever. Bull. Exp. Biol. Med. 11:1986;561-563.
16. Aisen P.S., Haines K.A., Given W., Abrahamson S.B., Pras M., Serhan C., Hamberg M., Samuelsson B., Weissman G. Circulating hydroxy fatty acids in familial Mediterranean fever. Proc. Natl. Acad. Sci. USA. 82:1985;1232-1236.
17. 4 in blood plasma of patients with familial Mediterranean fever. Bull. Exp. Biol. Med. 9:1990;296-297.
18. Nathan C., Xie Q.-W. Regulation of biosynthesis of NO. J. Biol. Chem. 269:1994;13725-13728.
19. Laskin J.D., Heck D.E., Laskin D.L. Multifunctional role of NO in inflammation. TEM. 5:1994;377-382.
20. Kim Y-M., Talanian R.V., Li J., Billiar T.R. NO prevents IL-1β and IFN-γ inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β-converting enzyme). J. Immunol. 161:1998;4122-4128.
21. Hierholzer C., Harbrecht B., Menezes J.M., Kane J., MacMicking J., Nathan C.F., Peitzman A.B., Billiar T.R., Tweardy D.J. Essential role of induced NO in the initiation of the inflammatory response after hemorrhagic shock. J. Exp. Med. 187:1998;917-928.
22. 15N into nitrate is enhanced by endotoxin treatment. Proc. Natl. Acad. Sci. USA. 60:1983;4581-4591.
23. Farrel A.J., Blanke D.G., Palmer R.M.J., Moncada S. Increased concentration of nitrite in synovial fluid and serum samples suggested increased NO synthesis in rheumatic diseases. Ann. Rheum. Dis. 51:1992;1219-1222.
24. Boockvar K.S., Granger D.I., Poston R.M. NO produced during murine listeriosis is protective. Infect. Immun. 62:1994;1089-1100.
25. Avontuur J.A., Stam T.C., Jongen-Lavrencic M., van Amsterdam J.G., Eggermont A.M., Bruining H.A. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNF alpha and nitrite/nitrate in human septic shock. Intensive Care Med. 24:1998;673-679.
26. Endo S., Inada K., Nakae H., Arakawa N., Takakuwa T., Yamada Y., Shimamura T., Suzuki T., Taniguchi S., Yoshida M. Nitrite/nitrate oxide (NOx) and cytokine levels in patients with septic shock. Res. Commun. Mol. Pathol. Pharmacol. 91:1996;347.
27. Roediger W.E.W., Lawson M.J., Nance S.H., Radcliffe B.C. Detectable colonic nitrate levels in inflammatory bowel diseases: mucosal or bacterial malfunction? Digestion. 35:1986;199-204.
28. Thomsen L.L., Brennum J., Iversen H.K., Olesen J. Effects of nitrogen oxide donor glyceryl trinitrate on pressure pain threshold in humans. Ugeskr. Laeger. 159:1997;4645-4648.
29. Ialenti A., Moncada S., Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 110:1993;701-706.
30. Amaryan G., Astvatsatryan V., Gabrielyan E., Panossian A., Panosyan V., Wikman G. Double-blind, placebo-controlled, randomised, pilot clinical trial of Immuno-Guard - a standardised fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim., Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with familial Mediterranean fever. Phytomedicine. 10:2003;271-285.
31. Jenke D.R. Chromatographic method validation: a review of current practices and procedures II. Guidelines for primary validation parameters. J. Liquid Chromatogr. Relat. Technol. 19:1996;737-757.
32. E. Erken, H.T.E. Ozer, R. Gunesacar, Plasma interleukin-12 levels in familial Mediterranean fever [abstract], in: Proceedings of the International Conference on Familial Mediterranean Fever II, Antalua, Turkey, vol. 74, 2000, p. B-9 (P).
33. Xie Q.W., Cho H.J., Calaycay J., Mumford R.A., Swiderek K.M., Lee T.D., Ding A., Troso T., Nathan C. Cloning and characterisation of inducible nitric oxide synthase from mouse macrophages. Science. 256:1992;225.
34. Kim Y.M., Son K. A nitric oxide production bioassay for interferon. J. Immunol. Methods. 198:1996;203.
35. Hickey M.J., Sharkey K.A., Sihota E.G., Reinhardt P.H., MacMicking J.D., Nathan C., Kubes P. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J. 11:1997;955.
36. Hartrick C.T. Increased production of nitric oxide stimulated by interferon-gamma from peripheral blood monocytes in patients with complex regional pain syndrome. Neurosci. Lett. 323:2002;75-77.
37. Tiao G., Rafferty J., Ogle C., Fischer J.E., Hasselgren P.O. Detrimental effect of nitric oxide synthase inhibition during endotoxemia may be caused by high levels of tumour necrosis factor and interleukin-6. Surgery. 116:1994;332-337.
38. Song D.K., Im Y.B., Jung J.S., Yan J.J., Huh S.O., Suh H.W., Kim Y.H. Central injection of nitric oxide synthase inhibitors increases peripheral interleukin-6 and serum amyloid A: involvement of adrenaline from adrenal medulla. Br. J. Pharmacol. 130:2000;41-48.
39. Goldfinger S.E. Colchicine for familial Mediterranean fever. N. Engl. J. Med. 287:1972;1302-1308.
40. Ozkan E., Okur O., Ekmekci A., Ozcan R., Tag T. A new approach to the treatment of periodic fever. Med. Bull. Istanbul. 5:1972;44-49.
41. Zemer D., Pras M., Sohar E., Modan M., Cabili S., Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N. Engl. J. Med. 314:1986;1001-1005.
42. Madav S.K., Tripathi H.C., Mishra T. Analgesic and anti-ulcerogenic effects of andrographolide. Indian J. Pharm. Sci. 57:1985;121-125.
43. Madav S., Tandan S.K., Lal J., Tripathi H.C. Anti-inflammatory activity of andrographolide. Fitoterapia. 67:1986;452-458.
44. Gupta P.P., Tandon J.S., Patnaik G.K. Anti-allergic activity of andrographolides isolated from Andrographis paniculata (Burm. F.) Wall. Pharm. Biol. 36:1998;72-74.
45. Singh V.K., All Z.A. Folk medicines in primary health care: common plants used for the treatment of fevers in India. Fitoterapia. 65:1994;68-74.
46. Amroyan E., Gabrielian E., Panossian A., Wikman G., Wagner H. Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation. Phytomedicine. 6:1999;27-31.
47. Chiou W.-F., Lin J.-J., Chen C.-F. Andrographolide suppresses the LPS-inducible expression of nitric oxide synthase in macrophages. Br. J. Pharmacol. 125:1998;327-334.
48. Panossian A., Davtyan T., Gukassyan N., Gukasova G., Mamikonyan G., Gabrielyan E., Wikman G. Effect of andrographolide and Kan Jang - fixed combination of extract SHA-10 and extract SHE-3 - on proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture. Phytomedicine. 9:2002;598-605.
49. M. Tunca, S. Akar, M. Soyturk, G. Kirkali, H. Resmi, H. Akhunlar, J.R. Gallimore, P.N. Hawkins, The effect of interferon on the inflammatory response during acute attacks of familial Mediterranean fever [abstract], in: Proceedings of the International Conference on Familial Mediterranean Fever II, Antalua, Turkey, 2000, p. 102.
50. M. Tunca, Colchicine update, in: Proceedings of the International Conference on Familial Mediterranean Fever II, Antalua, Turkey, 2000, pp. 50-52.
51. Tankurt E., Tunca M., Akbaylar H., Gonen O. Resolving familial Mediterranean fever attacks with interferon alpha. Br. J. Rheumatol. 35:1986;1188-1189.
52. Tunca M., Tankurt E., Akbaylar Akpinar H., Akar S., Hizli N., Gonen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br. J. Rheumatol. 36:1997;1005-1008.
53. Jung K.Y., Lee I.S., Oh S.R., Kim D.S., Lee H.-K. Lignans with platelet activating factor antagonist activity from Schizandra chinensis (Turcz.) Baill. Phytomedicine. 4:1997;229-231.
54. Lebedev A.A. Schizandra seed tincture and dibazole as means of non-specific profylaxis of acute respiratory infections during the peak of influenza at the beginning of 1969. Med. Zh. Uzbekistana. 6:1971;70-72.
55. Ohkura Y., Mizoguchi Y., Morisawa S., Takeda S., Aburada M., Hosoya E. Effect of gomisin A (TJN-101) on arachidonic acid cascade in macrophages. Japan J. Pharmacol. 52:1990;331-336.
56. E.V. Pavlushchenko, Pneumonia in aged and old people in conditions of the monsoon climate of the southern Primorskij region, in: New Data on Eleutherococcus and other Adaptogens, Izdat. DVNC AN SSSR, Vladivostok, 1981, pp. 119-122.
57. A.S. Shadrin, Yu.-G. Kustikova, N.A. Belogolovkina, N.I. Baranov, E.V. Oleinikova, V.P. Sigaeva, A.M. Ivlev, V.L. Romanov, L.I. Imkhanitskaya, S.G. Skripak, L.A. Ryazanova, Estimation of prophylactic and immunostimulating effects of Eleutherococcus and Schisandra chinensis preparations, in: Proceedings of the Second International Symposium New Data on Eleutherococcus, Part II, Meditsina, Moscow, 1984, pp. 289-293.
58. Fujita H. Anti-inflammatory effect of glycyrrhizinic acid. Effect of glycyrrhizinic acid against carrageenin-induced edema, UV-erythema and skin reaction sensitised with DCNB. Pharmacometrics. 19:1980;481-484.